PharmaCom BioVet, Inc. Announces Its Plans to Establish Its First Branded Veterinary Oncology Treatment Center in the Columbia,

  PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is
pleased to announce the company has located its first initial location to
begin the full-scale build out of the nation's first branded, dedicated
Veterinary Oncology Treatment Center.

The initial center is intended to be located at the Missouri Information Center located at the University of Missouri Life Science Business Incubator at Monsanto Place. The lease will be finalized within the next thirty days.

According to Sharon Berthold, Executive Vice President of PharmaCom BioVet, Inc., "Plans are underway to build and fully staff PharmaCom BioVet's first treatment center with some of the nations top Veterinary Oncologists. The company also plans to collaborate with partner firms, which are also located at Monsanto Place, to offer specialized care for companion animals suffering from all forms of cancer. A sales staff will be hired to market its niche Veterinary Oncology Treatment Centers to local non-specialized veterinarians. A marketing campaign will be initiated locally and commercials will be filmed and aired on local cable television. We expect to begin a rapid build out of our branded Veterinary Oncology Treatment Centers shortly after the opening of this flagship location."

About Us:

PharmaCom BioVet, Inc. (PHMB) is quickly positioning itself to becoming the leader in specialized veterinary oncology (cancer treatment facilities for animals). PHMB management is planning the rollout of specialized Veterinary Oncology Treatment Centers that will be strategically located throughout the United States. PHMB has licensed a series of proprietary devices and compounds that will enable animals suffering from cancer a greater life expectancy and decreased suffering.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Investor Relations Brian Holden 702-562-1287